IRB #

STUDY00015678

Title

A Phase 1a/1b Study of Cabiralizumab in Combination with Nivolumab in Patients with Selected Advanced Cancers

Principal Investigator

Matthew Taylor

Study Purpose

The study is being done to test any good and bad effects of Cabiralizumab and nivolumab (the study drugs) in men and women with advanced cancer.

Medical Condition(s)

Non-small cell lung cancer (NSCLC)
Melanoma
Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Pancreatic Cancer
Malignant Glioma
Anaplastic Thyroid

Eligibility Criteria

1. Men and women age 18 years or older
2. Locally advanced or metastatic solid tumors
3. Adequate organ function
4. Other criteria apply

Age Range

18 - 100

Healthy Volunteers Needed

No

Duration of Participation

Participants will receive the study drug as long as their cancer does not get worse and they do not develop side effects that they cannot tolerate. After the last dose of the study drug, participants will be contacted by phone every 3 months until the end of the study.

Minors Included

No

Contact

Knight Clinical Trials Information Line
503-494-1080

Sponsor

Five Prime Therapeutics, Inc.

Recruitment End

12/31/2025

Compensation Provided

No


Go Back